View Author
coxib tnsaid patient treatment study skin diseases disease tnsaid þ ppi nsaid hospitalization index date event netherland number practice diabetes follow-up coxib þ ppi incidence rate complication group incidence inhibitor gastroprotective index diabetes mellitus 100.0 children stage 2009 john wiley episode table control dutch incidence rates period pharmo mellitu adherence subject control subjects gastroprotection ulcer agent health gastroprotective agents class flammatory gi rf score erasmus mc population survey increase record characteristic duration cox -2 inhibitors factor gastroprotective strategies classi treatment groups consultation nonsteroidal strategy prescription classi fied drug safety outcome nsaid users prevalence arthritis van der linden database follow-up time atc code gi rf risk factors anti-in 0.0 guideline
